Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

V. Brodszky; P. Baji; O. Balogh; M. Péntek

doi:10.1007/s10198-014-0595-3

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

V. Brodszky, P. Baji, O. Balogh, M. Péntek

Bristol Medical School (THS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

110 Citations (Scopus)

Original language	English
Journal	European Journal of Health Economics
DOIs	https://doi.org/10.1007/s10198-014-0595-3
Publication status	Published - 2014

Access to Document

10.1007/s10198-014-0595-3

Handle.net

Persistent link

Cite this

@article{32dacf70271a46818c713f29087730a4,

title = "Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries",

author = "V. Brodszky and P. Baji and O. Balogh and M. P{\'e}ntek",

year = "2014",

doi = "10.1007/s10198-014-0595-3",

language = "English",

journal = "European Journal of Health Economics",

issn = "1618-7598",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

AU - Brodszky, V.

AU - Baji, P.

AU - Balogh, O.

AU - Péntek, M.

PY - 2014

Y1 - 2014

UR - https://www.scopus.com/pages/publications/84904338227

U2 - 10.1007/s10198-014-0595-3

DO - 10.1007/s10198-014-0595-3

M3 - Article (Academic Journal)

SN - 1618-7598

JO - European Journal of Health Economics

JF - European Journal of Health Economics

ER -

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

Access to Document

Handle.net

Other files and links

Cite this